OBJECTIVE: To obtain an unbiased estimate of the excess hospital length of stay (LOS) and cost attributable to extended-spectrum β-lactamase (ESBL) positivity in bloodstream infections (BSIs) due to Enterobacteriaceae. DESIGN: Retrospective cohort study. SETTING: A 2,200-bed academic medical center in Geneva, Switzerland. PATIENTS: Patients admitted during 2009. METHODS: We used multistate modeling and Cox proportional hazards models to determine the excess LOS and adjusted end-of-LOS hazard ratio (HR) for ESBL-positive and ESBL-negative BSI. We estimated economic burden as the product of excess LOS and average bed-day cost. Patient-level accounting data provided a complementary analysis of economic burden. A predictive model was fitted to national surveillance data. RESULTS: Thirty ESBL-positive and 96 ESBL-negative BSI cases were included. The excess LOS attributable to ESBL-positive and ESBL-negative BSI was 9.4 (95% confidence interval [CI], 0.4-18.4) and 2.6 (95% CI, 0.7-5.9) days, respectively. ESBL positivity was therefore associated with 6.8 excess days and CHF 9,473 per BSI. The adjusted end-of-LOS HRs for ESBL-positive and ESBL-negative BSI were 0.62 (95% CI, 0.43-0.89) and 0.90 (95% CI, 0.74-1.10), respectively. After reimbursement, the average financial loss per acute care episode in ESBL-positive BSI, ESBL-negative BSI, and control cohorts was CHF 48,674, 48,131, and 13,532, respectively. Our predictive model estimated that the nationwide cost of third-generation cephalosporin resistance would increase from CHF 2,084,000 in 2010 to CHF 3,526,000 in 2015. CONCLUSIONS: This is the first hospital-wide analysis of excess LOS attributable to ESBL positivity determined using multistate modeling to avoid time-dependent bias. These results may inform health-economic evaluations of interventions targeting ESBL control.
OBJECTIVE: To obtain an unbiased estimate of the excess hospital length of stay (LOS) and cost attributable to extended-spectrum β-lactamase (ESBL) positivity in bloodstream infections (BSIs) due to Enterobacteriaceae. DESIGN: Retrospective cohort study. SETTING: A 2,200-bed academic medical center in Geneva, Switzerland. PATIENTS: Patients admitted during 2009. METHODS: We used multistate modeling and Cox proportional hazards models to determine the excess LOS and adjusted end-of-LOS hazard ratio (HR) for ESBL-positive and ESBL-negative BSI. We estimated economic burden as the product of excess LOS and average bed-day cost. Patient-level accounting data provided a complementary analysis of economic burden. A predictive model was fitted to national surveillance data. RESULTS: Thirty ESBL-positive and 96 ESBL-negative BSI cases were included. The excess LOS attributable to ESBL-positive and ESBL-negative BSI was 9.4 (95% confidence interval [CI], 0.4-18.4) and 2.6 (95% CI, 0.7-5.9) days, respectively. ESBL positivity was therefore associated with 6.8 excess days and CHF 9,473 per BSI. The adjusted end-of-LOS HRs for ESBL-positive and ESBL-negative BSI were 0.62 (95% CI, 0.43-0.89) and 0.90 (95% CI, 0.74-1.10), respectively. After reimbursement, the average financial loss per acute care episode in ESBL-positive BSI, ESBL-negative BSI, and control cohorts was CHF 48,674, 48,131, and 13,532, respectively. Our predictive model estimated that the nationwide cost of third-generation cephalosporin resistance would increase from CHF 2,084,000 in 2010 to CHF 3,526,000 in 2015. CONCLUSIONS: This is the first hospital-wide analysis of excess LOS attributable to ESBL positivity determined using multistate modeling to avoid time-dependent bias. These results may inform health-economic evaluations of interventions targeting ESBL control.
Authors: Roberto Viau; Karen M Frank; Michael R Jacobs; Brigid Wilson; Keith Kaye; Curtis J Donskey; Federico Perez; Andrea Endimiani; Robert A Bonomo Journal: Clin Microbiol Rev Date: 2016-01 Impact factor: 26.132
Authors: Gabriel K Innes; Pranay R Randad; Anton Korinek; Meghan F Davis; Lance B Price; Anthony D So; Christopher D Heaney Journal: Annu Rev Public Health Date: 2020-01-07 Impact factor: 21.981
Authors: Joshua T Thaden; Yanhong Li; Felicia Ruffin; Stacey A Maskarinec; Jonathan M Hill-Rorie; Lisa C Wanda; Shelby D Reed; Vance G Fowler Journal: Antimicrob Agents Chemother Date: 2017-02-23 Impact factor: 5.191
Authors: Rasmus Leistner; Christian Sakellariou; Stephan Gürntke; Axel Kola; Ivo Steinmetz; Christian Kohler; Yvonne Pfeifer; Christoph Eller; Petra Gastmeier; Frank Schwab Journal: Infect Drug Resist Date: 2014-03-13 Impact factor: 4.003
Authors: Andrew J Stewardson; Arthur Allignol; Jan Beyersmann; Nicholas Graves; Martin Schumacher; Rodolphe Meyer; Evelina Tacconelli; Giulia De Angelis; Claudio Farina; Fabio Pezzoli; Xavier Bertrand; Houssein Gbaguidi-Haore; Jonathan Edgeworth; Olga Tosas; Jose A Martinez; M Pilar Ayala-Blanco; Angelo Pan; Alessia Zoncada; Charis A Marwick; Dilip Nathwani; Harald Seifert; Nina Hos; Stefan Hagel; Mathias Pletz; Stephan Harbarth Journal: Euro Surveill Date: 2016-08-18